Reprieve Cardiovascular
MA - MilfordBiotechnology
Focus: Reprieve Cardiovascular is a Series B biotech focused on fluid management solutions for heart failure, specifically targeting acute decompensated heart failure with a proprietary decongestion management system.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
SERIES B
Open Jobs
0
About Reprieve Cardiovascular
AI assessmentNot HiringNo open roles listed right now. Follow Reprieve Cardiovascular to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Fluid Management
Heart FailureClinical Trials (1)
NCT05015764Reprieve Cardiovascular System for the Treatment of Subjects With Acute Decompensated Heart Failure Mechanistic Study
N/AHelp build intelligence for Reprieve Cardiovascular
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.